Alembic Pharmaceuticals Ltd Stock Price Today (NSE: APLLTD)
Fundamental Score
Alembic Pharmaceuticals Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Alembic Pharmaceuticals Ltd share price today is ₹746.15, up +0.06% on NSE/BSE as of 17 June 2026. Alembic Pharmaceuticals Ltd (APLLTD) is a Mid-cap company in the Pharmaceuticals sector with a market capitalisation of ₹17.84K (Cr). The 52-week high for APLLTD share price is ₹1107.90 and the 52-week low is ₹635.80. At a P/E ratio of 28.12x, APLLTD is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 11.38% and a debt-to-equity ratio of 0.28.
Alembic Pharmaceuticals Ltd Share Price Chart — NSE/BSE Historical Performance
Alembic Pharmaceuticals Ltd share price chart: -1.22% return over the past month. 52-week high ₹1107.90, 52-week low ₹635.80.
Alembic Pharmaceuticals Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹723.70 | ₹729.00 | ₹706.90 | ₹725.50 | 41.80K (Cr) | |
| ₹736.00 | ₹738.90 | ₹713.40 | ₹720.00 | 78.22K (Cr) | |
| ₹754.95 | ₹760.65 | ₹724.95 | ₹736.10 | 1.34L (Cr) | |
| ₹763.95 | ₹763.95 | ₹749.00 | ₹754.20 | 49.29K (Cr) | |
| ₹762.30 | ₹780.75 | ₹757.00 | ₹759.60 | 1.33L (Cr) | |
| ₹764.95 | ₹764.95 | ₹753.00 | ₹762.30 | 91.87K (Cr) | |
| ₹754.50 | ₹765.00 | ₹743.65 | ₹755.70 | 1.93L (Cr) | |
| ₹755.85 | ₹756.10 | ₹745.00 | ₹748.90 | 98.56K (Cr) | |
| ₹751.10 | ₹762.25 | ₹736.55 | ₹752.35 | 68.95K (Cr) | |
| ₹728.00 | ₹768.50 | ₹727.55 | ₹751.10 | 2.20L (Cr) |
Alembic Pharmaceuticals Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹736.00 | ₹738.90 | ₹706.90 | ₹725.50 | -1.43% | |
| ₹759.95 | ₹809.00 | ₹710.70 | ₹736.10 | -3.14% | |
| ₹668.95 | ₹797.00 | ₹644.50 | ₹755.00 | +12.86% | |
| ₹700.00 | ₹725.35 | ₹635.80 | ₹663.25 | -5.25% | |
| ₹779.00 | ₹827.45 | ₹705.00 | ₹711.20 | -8.70% | |
| ₹843.00 | ₹849.00 | ₹744.75 | ₹783.20 | -7.09% | |
| ₹909.40 | ₹920.00 | ₹834.95 | ₹846.15 | -6.96% | |
| ₹897.40 | ₹998.00 | ₹885.70 | ₹907.20 | +1.09% | |
| ₹901.35 | ₹952.20 | ₹890.50 | ₹897.40 | -0.44% | |
| ₹931.00 | ₹984.80 | ₹885.00 | ₹901.35 | -3.18% | |
| ₹977.90 | ₹1002.00 | ₹913.40 | ₹936.95 | -4.19% | |
| ₹1024.80 | ₹1051.70 | ₹971.00 | ₹977.90 | -4.58% |
AI Research Briefing
Powered by Gemini · 2026-04-22
Alembic is a generics player trying to become something more, but negative profit CAGR and FDA risks make this a show-me story.
WHAT'S HAPPENING NOW (last 2-4 weeks)
Alembic Pharma launched its second 'Saksham Niveshak' campaign to help shareholders claim dividends and update KYC. Newspaper ads ran mid-April. Q4 FY26 results are expected in May 2026, with revenue estimated between -1,880 Cr and PAT between -200 Cr. The stock saw a 7.92% surge on April 8, outperforming the sector.
CORE STORY (THE REAL GAME)
Alembic is trying to transition from a generics player to a branded specialty pharma company, particularly in the US market. The Utility Therapeutics acquisition is key to this narrative.
- Q4 results expected in May 2026
- Recent price surge indicates renewed buying interest
- Saksham Niveshak campaign could unlock value
- Positive Q4 results and FY27 guidance
- Successful US branded product launch
- Further USFDA approvals
- High debt/equity in rising rate environment
- Negative profit CAGR
- USFDA scrutiny
Promoter holding stable at 69.74%. FII/DII activity is mixed.
Indian pharma sector benefiting from government initiatives like Biopharma SHAKTI and PLI schemes.
Free Cash Flow 5Y: ₹1236.03 Cr. Profit converting to cash.
Next 3-6 months hinge on Q4 results and US launch progress. Watch for USFDA developments.
Primary Thesis Risk
USFDA issues could derail the branded generics strategy.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Alembic Pharmaceuticals Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Alembic Pharmaceuticals Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of APLLTD across key market metrics for learning purposes.
Positive Indicators
8 factors identified
Strong Operating Margins (17.01%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Robust Profit Growth (28.80%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (15.91%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Conservative Debt Levels (D/E: 0.28)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (9.29x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹1236.03 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (69.74%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
2 factors identified
Weak Earnings Growth (-8.73% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (-7.96% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Alembic Pharmaceuticals Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Alembic Pharmaceuticals Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Alembic Pharmaceuticals LtdAlembic Pharmac...Selected✓ APLLTD • 533573 | 51/100 | ₹746.15₹746 | ₹17841.05₹17841.05 | 28.12Average 28.1 Average | 11.38%Average 11.38% Average | 13.05%Average 13.05% Average | 0.28Excellent 0.3 Excellent | -7.96%Poor -7.96% Poor | 7.69%Good 7.69% Good | 1.21% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1882.30₹1882 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6797.50₹6798 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4460.10₹4460 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1418.20₹1418 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1335.20₹1335 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2287.40₹2287 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹956.95₹957 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2492.60₹2493 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1435.90₹1436 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5451.50₹5452 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
Alembic Pharmaceuticals Ltd PE Ratio History
Historical price-to-earnings ratio for APLLTD — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹29.68 | ₹846.15 | 28.5x |
| FY 2024 | ₹31.33 | ₹1066.25 | 34x |
| FY 2023 | ₹17.40 | ₹759.40 | 43.6x |
| FY 2022 | ₹26.50 | ₹572.90 | 21.6x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Alembic Pharmaceuticals Ltd Dividend History
Annual cash dividends paid by APLLTD — dividend yield 1.21%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹216.22 Cr |
| FY 2024 | ₹157.25 Cr |
| FY 2023 | ₹196.56 Cr |
| FY 2022 | ₹275.19 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Alembic Pharmaceuticals Ltd Quarterly Performance
Latest quarterly metrics for APLLTD — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
15.91%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
28.80%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
7.69%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
-7.96%
Compounded annual net profit growth over 5 years
Alembic Pharmaceuticals Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for APLLTD — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Alembic Pharmaceuticals Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Alembic Pharmaceuticals Ltd (APLLTD) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Alembic Pharmaceuticals Ltd
About APLLTD (Alembic Pharmaceuticals Ltd)
Alembic Pharmaceuticals Ltd is a dynamic and multifaceted player in the global pharmaceutical arena, deeply rooted in a rich legacy of scientific innovation and unwavering commitme...nt to healthcare. The company operates with a broad spectrum of capabilities, spanning the entire pharmaceutical value chain, from meticulous research and development to advanced manufacturing processes and strategic marketing initiatives. Their dedication to quality and precision ensures that every product meets the highest international standards, delivering safe and effective treatments to patients across diverse therapeutic areas. Alembic Pharmaceuticals Ltd embodies a relentless pursuit of excellence, constantly pushing the boundaries of pharmaceutical science to address unmet medical needs and improve patient outcomes. Driven by a patient-centric philosophy, Alembic Pharmaceuticals Ltd crafts a diverse portfolio of pharmaceutical solutions targeting a wide range of prevalent and emerging health challenges. This includes developing innovative formulations and generics across various therapeutic specialties, such as cardiovascular health, musculoskeletal disorders, metabolic diseases, and ophthalmic conditions. The company's relentless focus on research and development allows them to stay at the forefront of pharmaceutical advancements, continuously introducing new and improved treatment options to healthcare providers and patients alike. Furthermore, Alembic Pharmaceuticals Ltd is committed to fostering strategic partnerships and collaborations, expanding their reach and impact within the global healthcare landscape. Alembic Pharmaceuticals Ltd distinguishes itself through its unwavering dedication to ethical business practices, environmental sustainability, and social responsibility. They operate with transparency and integrity in all aspects of their business, ensuring compliance with the most stringent regulatory standards and fostering trust with stakeholders. The company also recognizes the importance of environmental stewardship and actively implements sustainable practices to minimize its environmental footprint. In addition, Alembic Pharmaceuticals Ltd is deeply committed to giving back to the community through various social initiatives, supporting education, healthcare, and other programs that improve the quality of life for individuals and families in need.
Company Details
Key Leadership
Corporate Events
APLLTD Share Price: Frequently Asked Questions
What is the current share price of Alembic Pharmaceuticals Ltd?
Alembic Pharmaceuticals Ltd (APLLTD) trades at ₹746.15 on NSE and BSE. Market cap ₹17.84K (Cr). Educational data only.
What is the P/E ratio of Alembic Pharmaceuticals Ltd?
Alembic Pharmaceuticals Ltd has a P/E of 28.12x vs industry average 31.77x.
What is the Bull Run score for Alembic Pharmaceuticals Ltd?
Alembic Pharmaceuticals Ltd has a Bull Run score of 51/100 based on 25+ financial parameters.
Does Alembic Pharmaceuticals Ltd pay dividends?
Alembic Pharmaceuticals Ltd has a dividend yield of 1.21%. Past dividends don't guarantee future payments.
What is the ROE of Alembic Pharmaceuticals Ltd?
Alembic Pharmaceuticals Ltd has ROE of 11.38%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Alembic Pharmaceuticals Ltd?
Alembic Pharmaceuticals Ltd has debt-to-equity of 0.28.
Is Alembic Pharmaceuticals Ltd a good investment?
Bull Run gives Alembic Pharmaceuticals Ltd a score of 51/100. This is not investment advice — consult a SEBI-registered advisor.